Hyperphosphatemia

Risk of Nonspinal Fracture Increased in Moderate to Severe CKD

Publish Date October 13, 2020

Fracture prevention efforts should be considered in patients with CKD of any age, according to investigators.

Tenapanor Under Review for Hyperphosphatemia in CKD

Publish Date September 18, 2020

Tenapanor is a first-in-class oral medication that works by blocking the NHE3 transporter in the gastrointestinal tract.

High Serum Phosphate Concentration May Be Associated With Greater MALE Risk in Hemodialysis

Publish Date June 26, 2020

Elevated serum phosphate concentration may be associated with an increased risk for major adverse limb events in patients undergoing hemodialysis.

Iron-Based Phosphate Binder Is Effective, Does Not Cause Iron Overload

Publish Date March 12, 2020

A study of stable dialysis patients receiving sucroferric oxyhydroxide found no significant changes in hemoglobin, ferritin level, and transferrin saturation.

Tighter Phosphate Control in HD May Slow Coronary Artery Calcification

Publish Date December 16, 2019

Achieving serum phosphate levels of 3.5 to 4.5 mg/dL vs 5.0 to 6.0 mg/dL in patients on hemodialysis was associated with less coronary artery calcification, study findings suggest.

Elevated Phosphate Worsens Inpatient Outcomes Regardless of Renal Function

Publish Date December 13, 2019

In a study of hospitalized patients, increased serum phosphate levels significant increased the risk of acute kidney injury, end-stage renal disease, and death.

Hyperphosphatemia in HD May Raise Risk for Peripheral Artery Disease

Publish Date December 12, 2019

In a study of hemodialysis patients, PAD risk increased nonlinearly with serum phosphate level.

Tenapanor May Improve Uncontrolled Hyperphosphatemia

Publish Date December 11, 2019

By blocking paracellular phosphate transport, tenapanor added to phosphate binders may improve the hyperphosphatemia management in patients on maintenance dialysis, a study found.

Elevated FGF23 Linked to Mortality in Type 2 Diabetes

Publish Date October 10, 2019

In a study, elevated FGF23 was associated with increased risks of major adverse cardiovascular events and mortality in type 2 diabetes patients with normal or mildly impaired kidney function.

Elevated Phosphate May Be Detrimental Even Without CKD

Publish Date October 9, 2019

If confirmed, findings from 2 new studies would have important clinical implications for phosphate intake in the general population.